Evaluation of the Knowledge and Attitude of COVID-19 Vaccines Among Pilgrims

Although vaccines are recognized as one of the most successful public health measures, some individuals consider vaccination unsafe, ineffective, and unnecessary. The study aimed to evaluate knowledge and attitude of COVID-19 vaccines among pilgrims at a Hajj event (pilgrimage). A survey was conducted to assess knowledge and attitude toward COVID-19 vaccines among 251 pilgrims in Makkah City, Saudi Arabia. The results showed a moderate level of knowledge, with a mean of 76.1%. The majority (94.8%) of the participants know that “the COVID-19 vaccines are effective” followed by their knowledge “about the purpose of the vaccine” (84.5%). There was poor knowledge regarding the different types of COVID-19 vaccines (66.1%) and how they should be stored (66.1%). There was a strong agreement about the effectiveness of COVID-19 vaccines and to be taken during pilgrimage with a mean value of 4.4382 and 4.2311 respectively. Most pilgrims (46.6%) get awareness about COVID-19 vaccines from the official media, and social media (29.0%). There was a significant association between gender and the type of vaccines (P < 0.05). The Pfizer BioNTech vaccine was the most common vaccine used during the Hajj event (50.4%), followed by AstraZeneca (29.0%), Johnson & Johnson (24.7%), and Moderna (23.1%). It was concluded that there was a moderate level of knowledge and positive attitude regarding COVID-19 vaccines. Also, there was a strong agreement among pilgrims about the effectiveness of COVID-19 vaccines and the fact that they should be taken by all pilgrims.

1.        Alzahrani AG, Choudhry AJ, Al Mazroa MA, Turkistani AH, Nouman GS, Memish ZA. Pattern of diseases among visitors to Mina health centers during the Hajj season, 1429 H (2008 G). J Infect Public Health. 2012;5(1):22-34.

2.        Fatani MI, Al-Afif KA, Hussain H. Pattern of skin diseases among pilgrims during Hajj season in Makkah, Saudi Arabia. Int J Dermatol. 2000;39(7):493-6.

3.        Hillary VE, Ceasar SA. An update on COVID-19: SARS-CoV-2 variants, antiviral drugs, and vaccines. Heliyon. 2023;9(3):e13952.

4.        Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, et al. Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med. 2020;46(1):3-16.

5.        Zhang C, Wang H, Wen Z, Bao Z, Li X. Collective and Individual Assessment of the Risk of Death from COVID-19 for the Elderly, 2020-2022. China CDC Wkly. 2023;5(18):407-12.

6.        Gupta A, Singh AP, Singh VK, Sinha RP. Recent Developments and Future Perspectives of Vaccines and Therapeutic Agents against SARS-CoV2 Using the BCOVS1CTD of the S Protein. Viruses. 2023;15(6):1234.

7.        Tian Y, Hu D, Li Y, Yang L. Development of therapeutic vaccines for the treatment of diseases. Mol Biomed. 2022;3(1):40.

8.        Finsterer J. SARS-CoV-2 vaccinations are unsafe for those experiencing post-vaccination Guillain-Barre syndrome. Ann Med Surg (Lond). 2021;68:102584.

9.        Gotlib J, Sobierajski T, Jaworski M, Wawrzuta D, Borowiak E, Dobrowolska B, et al. "Vaccinate, Do Not Hesitate!". Vaccination Readiness against COVID-19 among Polish Nursing Undergraduate Students: A National Cross-Sectional Survey. Vaccines (Basel). 2021;9(9):1029.

10.      Widdess-Walsh P. Don't Hesitate to Vaccinate-The Safety of Covid-19 Vaccination and Epilepsy. Epilepsy Curr. 2023;23(1):18-9.

11.      Al-Tawfiq JA, Kattan RF, Memish ZA. Escalating the 2022 Hajj during the third year of the COVID-19 pandemic. J Travel Med. 2022;29(6):taac059.

12.      Yarlagadda H, Patel MA, Gupta V, Bansal T, Upadhyay S, Shaheen N, et al. COVID-19 Vaccine Challenges in Developing and Developed Countries. Cureus. 2022;14(4):e23951.

13.      Bhartiya SKN, Singh T, Murugan S, Rajavel S, Wadhwani M. Knowledge, attitude and practice towards COVID-19 vaccination acceptance in West India. Int J Community Med Public Health. 2021;8(3):1170-6

14.      Sengupta M, Dutta S, Roy A, Chakrabarti S, Mukhopadhyay I. Knowledge, attitude and practice survey towards COVID-19 vaccination: A mediation analysis. Int J Health Plann Manage. 2022;37(4):2063-80.

15.      Abebe H, Shitu S, Mose A. Understanding of COVID-19 Vaccine Knowledge, Attitude, Acceptance, and Determinates of COVID-19 Vaccine Acceptance Among Adult Population in Ethiopia. Infect Drug Resist. 2021:2015-25.

16.      Del Riccio M, Bechini A, Buscemi P, Bonanni P. On Behalf of the Working Group D, Boccalini S. Reasons for the Intention to Refuse COVID-19 Vaccination and Their Association with Preferred Sources of Information in a Nationwide, Population-Based Sample in Italy, before COVID-19 Vaccines Roll Out. Vaccines (Basel). 2022;10(6):913.

17.      Chirico F, Teixeira da Silva JA, Tsigaris P, Sharun K. Safety & effectiveness of COVID-19 vaccines: A narrative review. Indian J Med Res. 2022;155(1):91-104.

18.      Chen J, Huang B, Deng Y, Wang W, Zhai C, Han D, et al. Synergistic Immunity and Protection in Mice by Co-Immunization with DNA Vaccines Encoding the Spike Protein and Other Structural Proteins of SARS-CoV-2. Vaccines (Basel). 2023;11(2):243.

19.      Papagiannis D, Malli F, Raptis DG, Papathanasiou IV, Fradelos EC, Daniil Z, et al. Assessment of knowledge, attitudes, and practices towards new coronavirus (SARS-CoV-2) of health care professionals in Greece before the outbreak period. Int J Environ Res Public Health. 2020;17(14):4925.

20.      Al-Marshoudi S, Al-Balushi H, Al-Wahaibi A, Al-Khalili S, Al-Maani A, Al-Farsi N, et al. Knowledge, Attitudes, and Practices (KAP) toward the COVID-19 Vaccine in Oman: A Pre-Campaign Cross-Sectional Study. Vaccines (Basel). 2021;9(6):602.

21.      Bakdash T, Marsh C. Knowledge, Attitudes, and Beliefs Regarding the COVID-19 Pandemic Among Women in Kansas. J Community Health. 2021;46(6):1148-54.

22.      Gibbons E, Stein C, Springer J, Roemhild E, Meadows E, Dowling J. Knowledge, Attitudes, and Beliefs of Pediatric Health Care Workers: Understanding the Response to COVID-19. J Pediatr Health Care. 2022;36(4):305-9.

23.      Mahmud S, Mohsin M, Khan IA, Mian AU, Zaman MA. Knowledge, beliefs, attitudes and perceived risk about COVID-19 vaccine and determinants of COVID-19 vaccine acceptance in Bangladesh. PLoS One. 2021;16(9):e0257096.

24.      Amarin JZ, Hayek H, Halasa NB. COVID-19 vaccines protect children of all ages. J Clin Invest. 2022;132(17):e164102.

25.      Krug PW, Wang L, Shi W, Kong WP, Moss DL, Yang ES, et al. EV-D68 virus-like particle vaccines elicit cross-clade neutralizing antibodies that inhibit infection and block dissemination. Sci Adv. 2023;9(20):eadg6076.

26.      Riad A, Alsaad SS, Almurikhi AA, Alzahrani FA, Alghamdi AM, Alzaid EH, et al. Side Effects of COVID-19 Vaccines Primer Doses: Experience of Saudi Healthcare Workers Participating in CoVaST-SA. Vaccines (Basel). 2022;10(12):2137.

27.      Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021;397(10285):1646-57.

28.      Marcec R, Likic R. Using Twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines. Postgrad Med J. 2022;98(1161):544-50.

29.      El-Shitany NA, Harakeh S, Badr-Eldin SM, Bagher AM, Eid B, Almukadi H, et al. Minor to Moderate Side Effects of Pfizer-BioNTech COVID-19 Vaccine Among Saudi Residents: A Retrospective Cross-Sectional Study. Int J Gen Med. 2021:1389-401.

30.      Atanasov V, Barreto N, Whittle J, Meurer J, Weston BW, Luo QE, et al. Selection Effects and COVID-19 Mortality Risk after Pfizer vs. Moderna Vaccination: Evidence from Linked Mortality and Vaccination Records. Vaccines (Basel). 2023;11(5):971.

31.      Katoto PD, Tamuzi JL, Brand AS, Marangu DM, Byamungu LN, Wiysonge CS, et al. Effectiveness of COVID-19 Pfizer-BioNTech (BNT162b2) mRNA vaccination in adolescents aged 12-17 years: A systematic review and meta-analysis. Hum Vaccin Immunother. 2023;19(1):2214495.

32.      Wolszczak Biedrzycka B, Bienkowska A, Smolinska-Fijolek E, Biedrzycki G, Dorf J. The Influence of Two Priming Doses of Different Anti-COVID-19 Vaccines on the Production of Anti-SARS-CoV-2 Antibodies After the Administration of the Pfizer/BioNTech Booster. Infect Drug Resist. 2022;15:7811-21.

33.      Kudlay D, Svistunov A, Satyshev O. COVID-19 Vaccines: An Updated Overview of Different Platforms. Bioengineering (Basel). 2022;9(11):714.

34.      Rodrigues CMC, Plotkin SA. Impact of Vaccines; Health, Economic and Social Perspectives. Front Microbiol. 2020;11:1526.

35.      Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2021;384(5):403-16.

36.      Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412-23.

37.      Green MS, Abdullah R, Vered S, Nitzan D. A study of ethnic, gender and educational differences in attitudes toward COVID-19 vaccines in Israel - implications for vaccination implementation policies. Isr J Health Policy Res. 2021;10(1):26.

38.      Shapiro JR, Privor-Dumm L, Rosser EN, Leng SX, Klein SL, Morgan R. The intersection of gender and race in older adults' decision to receive COVID-19 vaccines. Vaccine. 2023;41(1):211-8.

39.      Fleming JA, Baral R, Higgins D, Khan S, Kochar S, Li Y, et al. Value profile for respiratory syncytial virus vaccines and monoclonal antibodies. Vaccine. 2023.

40.      Hajissa K, Mutiat HA, Kaabi NA, Alissa M, Garout M, Alenezy AA, et al. COVID-19 Vaccine Acceptance and Hesitancy among Migrants, Refugees, and Foreign Workers: A Systematic Review and Meta-Analysis. Vaccines (Basel). 2023;11(6):1070.

41.      Shinjoh M, Furuichi M, Tsuzuki S, Iqbal A, Fukushima N, Soen S, et al. Effectiveness of inactivated influenza and COVID-19 vaccines in hospitalized children in 2022/23 season in Japan - The first season of co-circulation of influenza and COVID-19. Vaccine. 2023;41(33):4777-81.